WELLESLEY HILLS, Mass., April 2, 2008 /CNW/ -- Joseph F. Finn, Jr., CPA,
the Assignee for the Benefit of Creditors of ActivBiotics, announced today the
completion of the sale of ActivBiotics intellectual property assets for $3.5
million. The assets consisted of 1) Rifalazil, a Phase II antibiotic, 2) a
library of novel rifamycin compounds, and 3) a clinical stage superoxide
dismutase mimetic (SODm) and a library of SODm small molecules.
